Spero R Cataland
Overview
Explore the profile of Spero R Cataland including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
73
Citations
1801
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Volker L, Brinkkoetter P, Cataland S, Masias C
J Thromb Haemost
. 2023 Aug;
21(10):2718-2725.
PMID: 37562668
Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a rare hematologic disease caused by autoantibodies against ADAMTS-13 that trigger microangiopathic hemolytic anemia. Therapeutic plasma exchange and glucocorticoids have been the mainstay of...
12.
Chaturvedi S, Antun A, Farland A, Woods R, Metjian A, Park Y, et al.
Blood
. 2022 Jul;
140(12):1335-1344.
PMID: 35797471
Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is characterized by recurring episodes of thrombotic microangiopathy, causing ischemic organ impairment. Black patients are overrepresented in iTTP cohorts in the United States, but racial...
13.
Akwaa F, Antun A, Cataland S
Blood
. 2022 Jun;
140(5):438-444.
PMID: 35667044
Immune-mediated thrombocytopenic purpura (iTTP) is a thrombotic microangiopathy characterized by an acquired ADAMTS13 deficiency as a result of the presence of an antibody inhibitor of ADAMTS13 leading to the formation...
14.
Deucher W, Sukumar S, Cataland S
Res Pract Thromb Haemost
. 2022 Feb;
6(1):e12658.
PMID: 35155977
De novo and relapsed immune-mediated thrombotic thrombocytopenic purpura (iTTP) have been documented to have occurred following severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccination. Here, we present a case of...
15.
Sukumar S, Brodsky M, Hussain S, Yanek L, Moliterno A, Brodsky R, et al.
Blood Adv
. 2021 Aug;
6(4):1264-1270.
PMID: 34461629
Immune-mediated thrombotic thrombocytopenic purpura (iTTP) survivors experience high rates of adverse health sequelae and increased mortality over long-term follow-up. We conducted this multicenter cohort study to evaluate long-term mortality and...
16.
Brodsky M, Sukumar S, Selvakumar S, Yanek L, Hussain S, Mazepa M, et al.
Am J Hematol
. 2021 Aug;
96(12):1587-1594.
PMID: 34460124
Cardiovascular disease is a leading cause of death in survivors of immune-mediated thrombotic thrombocytopenic purpura (iTTP), but the epidemiology of major adverse cardiovascular events (MACE) in iTTP survivors is unknown....
17.
Sukumar S, Lammle B, Cataland S
J Clin Med
. 2021 Feb;
10(3).
PMID: 33540569
Thrombotic thrombocytopenic purpura (TTP) is a rare thrombotic microangiopathy characterized by microangiopathic hemolytic anemia, severe thrombocytopenia, and ischemic end organ injury due to microvascular platelet-rich thrombi. TTP results from a...
18.
Cuker A, Cataland S, Coppo P, Rubia J, Friedman K, George J, et al.
Blood
. 2021 Feb;
137(14):1855-1861.
PMID: 33529333
Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a potentially fatal thrombotic microangiopathy caused by autoantibody-mediated severe deficiency of ADAMTS13. Standardized definitions of response, exacerbation, remission, and relapse were initially proposed in...
19.
Zheng X, Vesely S, Cataland S, Coppo P, Geldziler B, Iorio A, et al.
J Thromb Haemost
. 2020 Sep;
18(10):2486-2495.
PMID: 32914582
Background: Despite an increase in our understandings of pathogenesis of thrombotic thrombocytopenic purpura (TTP), the approaches for initial diagnosis and management of TTP vary significantly. Objective: The evidence-based guidelines of...
20.
Zheng X, Vesely S, Cataland S, Coppo P, Geldziler B, Iorio A, et al.
J Thromb Haemost
. 2020 Sep;
18(10):2503-2512.
PMID: 32914535
Background: Despite advances in treatment options for thrombotic thrombocytopenic purpura (TTP), there are still limited high quality data to inform clinicians regarding its management. Methods: In June 2018, the ISTH...